We’re looking forward to seeing you in Orlando, Florida, for the HealthTrust University Conference. From August 12-13 we’ll be sharing about oncology solutions at booth #1024.
NeoGenomics Laboratories
Hospitals and Health Care
Fort Myers, Florida 31,684 followers
One Lab. Vital Answers.
About us
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
- Website
-
http://neogenomics.com
External link for NeoGenomics Laboratories
- Industry
- Hospitals and Health Care
- Company size
- 1,001-5,000 employees
- Headquarters
- Fort Myers, Florida
- Type
- Public Company
- Founded
- 2002
- Specialties
- Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
Locations
-
Primary
9490 NeoGenomics Way
Fort Myers, Florida 33912, US
Employees at NeoGenomics Laboratories
Updates
-
This year, NeoGenomics signed the Working with Cancer Pledge. By taking the pledge, NeoGenomics demonstrates its commitment to supporting team members living with or caring for a loved one with cancer. To read the full press release, please visit: https://lnkd.in/gdUsd63s #NeoGenomics #WorkingWithCancer #Oncology #PatientCare . . . 1: British Journal of Cancer and International Agency for Research on Cancer (IARC) - Est number of new cases. all cancers, sexes, ages (2020 2: National Cancer Institute, https://lnkd.in/d5aKa4X 3: Publicis Custom Research
-
-
#NeoGenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: https://lnkd.in/gNxygjTB #OvarianCancer #CancerTesting #Oncology
-
-
The Emergence of Multi-modal Real-world data: The power of Clinico-Genomic data versus traditional RWD Sources is a new #whitepaper that explores crucial and emerging topics, such as: • Why biomarker and genomic data matters for life science • How these data sources unlock what’s been missing from traditional RWD sources • How these newly created longitudinal data sets support drug development from discovery to trial to post-market • Why longitudinal data matters for developing targeted treatments for rare or complex conditions such as multiple myeloma • How tokenization allows for better integration of disparate data sources and meets the scrutiny of peer review and regulatory approval Visit us online to read this whitepaper: https://lnkd.in/gRYNims7 #NeoGenomics #RWD #Oncology
-
NeoGenomics is pleased to share a newly released lite paper, “Examining RET Fusions: How Real-World Data (RWD) can be used to support a Tumor-Agnostic Era.” In recent years, the FDA has approved specific therapies that are of high interest due to their potential applications in a tumor-agnostic setting. As precision oncology moves toward a targeted pan-tumor paradigm, an understanding of prevalence rates and testing patterns is critical for commercial execution and uptake. Visit us online to learn more: https://lnkd.in/e86mB_8Q
-
-
Our very own, Brittany Bell, was nominated as an ASCP (American Society for Clinical Pathology) 40 Under Forty Nominee. This program recognizes members under the age of 40 for their leadership and achievements who are making an impact on pathology and laboratory medicine. Please take a minute to vote for Brittany to advance to the ASCP 40 Under Forty Top Five. You can vote once per day until July 22nd. Vote Now: 2024 40 Under Forty Honorees (https://lnkd.in/ekr8_c-j)
-
-
Protecting your skin can help prevent cancer. #Summer is an important time to share tips that help protect against harmful UV rays. Help us spread education and embrace sun-safe habits. #SkinCancerAwareness #SunSafety #ProtectYourSkin
-
-
We’re pleased to share an update within the industry: An FDA committee recently unanimously ruled that MRD is a viable endpoint for Multiple Myeloma clinical trials. Learn more about how the NeoGenomics Pharma Services team can support your Multiple Myeloma trials with our clinical-grade MRD tests: https://lnkd.in/gxtNjn-a #MultipleMyeloma #MM #MRD #MinimalResidualDisease #Flow #FlowCytometry
-
-
Summertime may be synonymous with spending time outdoors, but it’s important to take precautions. The Skin Cancer Foundation recommends that you: • Seek the shade, especially between 10 AM and 4 PM. • Avoid tanning, and never use UV tanning beds. • Use a broad-spectrum (UVA/UVB) sunscreen with an SPF of 15 or higher every day. For extended outdoor activity, use a water-resistant, broad- spectrum (UVA/UVB) sunscreen with an SPF of 30 or higher. • Examine your skin head-to-toe every month. For more tips, visit them at: https://lnkd.in/gpr8PhB #NeoGenomics #SkinCancer #CancerTesting